Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Apr 2;11(1):7463.
doi: 10.1038/s41598-021-86769-z.

Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis

Luigi Cirillo  1 , Chiara Somma  1 , Marco Allinovi  2 , Alfredo Bagalà  1 , Giuseppe Ferro  1 , Elio Di Marcantonio  1 , Stefania Bellelli  3 , Lorenzo Antonio Dallari  1 , Piercarlo Ballo  4 , Pietro Claudio Dattolo  5
Affiliations
Observational Study

Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis

Luigi Cirillo et al. Sci Rep. .

Abstract

In non-dialysis-dependent chronic kidney disease (NDD-CKD), erythropoiesis-stimulating agents (ESAs) and iron supplementation are essential for anemia management. Ferric carboxymaltose (FCM) is a relatively novel intravenous iron formulation used in different clinical settings, although scarce data exist in NDD-CKD patients. Primary objective of this study was to retrospectively evaluate the efficacy of FCM compared with oral ferrous sulfate for the treatment of iron-deficiency anemia in a cohort of NDD-CKD patients, considering also the treatment costs. This was a monocentric, retrospective observational study reviewing 349 NDD-CKD patients attending an outpatient clinic between June 2013 and December 2016. Patients were treated by either FCM intravenous infusion or oral ferrous sulfate. We collected serum values of hemoglobin, ferritin and transferrin saturation (TSAT) and ESAs doses at 12 and 18 months. The costs related to both treatments were also analysed. 239 patients were treated with FCM intravenous infusion and 110 patients with oral ferrous sulfate. The two groups were not statistically different for age, BMI and eGFR values. At 18 months, hemoglobin, serum ferritin and TSAT values increased significantly from baseline in the FCM group, compared with the ferrous sulfate group. ESAs dose and rate of infusion decreased only in the FCM group. At 18 months, the treatment costs, analysed per week, was higher in the ferrous sulfate group, compared with the FCM group, and this was mostly due to a reduction in ESAs prescription in the FCM group. Routine intravenous FCM treatment in an outpatient clinic of NDD-CKD patients results in better correction of iron-deficiency anemia when compared to ferrous sulfate. In addition to this, treating NDD-CKD patients with FCM leads to a significant reduction of the treatment costs by reducing ESAs use.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Cost of therapy (including ESAs cost) per person/week for patients treated with FCM and ferrous sulfate (FS) by time of treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Weiss G, Goodnough LT. Anemia of chronic disease. N. Engl. J. Med. 2005;352:1011–1023. doi: 10.1056/NEJMra041809. - DOI - PubMed
    1. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak JN. Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study. Am. Heart J. 2006;151:492–500. doi: 10.1016/j.ahj.2005.03.055. - DOI - PubMed
    1. Kassebaum, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615–624. doi: 10.1182/blood-2013-06-508325. - DOI - PMC - PubMed
    1. De Nicola L, et al. For the SINTABLECDK Study Group. Prevalence and prognosis of mild anemia in non-dialysis chronic kidney disease: A prospective cohort study in outpatient renal clinics. Am. J. Nephrol. 2010;32:533–540. doi: 10.1159/000321468. - DOI - PubMed
    1. Del Vecchio, L., etal. For the ERA-EDTA European Renal and Cardiovascular Medicine Working (EURECA-m) Group. Intravenous iron therapy and the cardiovascular system: Risks and benefits. Clin.Kidney J. sfaa212 (2020). - PMC - PubMed

Publication types

MeSH terms